Formoterol is a long-acting bronchodilator that keeps the airways of the lungs open for up to 12 hours per dose. It is used in the management of asthma and chronic obstructive pulmonary disease (COPD) to reduce breathlessness, wheezing and chest tightness. In India, formoterol is most widely prescribed as Foracort that is a fixed-dose combination with the inhaled corticosteroid budesonide and is available as a dry powder inhaler, pressurised metered-dose inhaler (pMDI) and nebuliser solution. Formoterol is a LABA and must always be prescribed alongside an inhaled corticosteroid in asthma.

Drug Class: Long-Acting Beta-2 Agonist (LABA) Explained

Beta-2 agonists stimulate beta-2 adrenergic receptors in the smooth muscle surrounding the airways, causing airway widening. LABAs like formoterol provide this effect for 12 hours unlike short-acting beta-2 agonists (SABAs) such as salbutamol, which only last 4 to 6 hours. Formoterol is unique among LABAs because it also has a rapid onset of 1 to 3 minutes making it suitable for use as both a controller (regular maintenance) and a reliever (as needed) in asthma, a strategy called MART (Maintenance and Reliever Therapy).

Medical Uses

Doctors prescribe formoterol for:

• Asthma: Used as regular maintenance therapy (twice daily) in patients whose asthma is not adequately controlled on inhaled corticosteroids alone; always combined with an inhaled corticosteroid, never used as monotherapy in asthma

• COPD: Used as regular maintenance therapy in moderate to severe COPD to reduce breathlessness, improve exercise tolerance and reduce exacerbations; can be used as LABA monotherapy in COPD (unlike in asthma)

• MART (Maintenance and Reliever Therapy): A strategy specific to formoterol-ICS combinations; patients use their combination inhaler both as daily maintenance and as a reliever when symptoms occur; this approach reduces exacerbation rates and total steroid exposure

• Exercise-induced bronchoconstriction: Formoterol can be used before exercise to prevent exercise-induced airway narrowing

Formoterol Inhaler, Nebuliser and Respules: Forms Compared

• Dry powder inhaler (DPI): The most common form in India; requires a moderate-to-strong inhalation effort; not suitable for acute attacks when the patient cannot generate sufficient inspiratory flow

• Pressurised metered-dose inhaler (pMDI): Requires coordination between pressing the canister and inhaling; a spacer device is recommended, particularly in children and older adults

• Nebuliser solution (respules): Formoterol 20 mcg per 2 mL ampules; suitable for young children and severely breathless patients and during acute exacerbations.

What Is Foracort? (Formoterol + Budesonide Combination)

Foracort is the most widely prescribed combination inhaler in India for asthma and COPD. It contains formoterol (6 mcg or 12 mcg) combined with budesonide (100 mcg, 200 mcg or 400 mcg). Budesonide reduces airway inflammation that is the underlying cause of asthma. The combination addresses both the inflammatory and bronchospastic components of asthma simultaneously. Foracort 200 (budesonide 200 mcg/formoterol 6 mcg) is widely available across India. The MART strategy uses Foracort as both daily controller and as-needed reliever - reducing exacerbations significantly compared to fixed-dose regimens.

Common and Serious Side Effects

Common side effects:

• Tremor: Fine trembling of the hands; the most common side effect of beta-2 agonists; usually transient and dose-related

• Palpitations and tachycardia: Formoterol has some residual beta-1 cardiac activity; generally mild with inhaled doses; more pronounced with nebuliser doses

• Headache: Commonly reported; usually mild and transient

• Throat irritation and cough: From the dry powder or propellants; rinsing the mouth after use reduces oropharyngeal side effects.

Serious side effects:

• Hypokalaemia: Beta-2 agonists shift potassium into cells, lowering serum potassium; clinically significant at high doses or in combination with diuretics and corticosteroids; can trigger cardiac arrhythmias

• Paradoxical bronchospasm: Rarely formoterol can trigger sudden airway narrowing immediately after inhalation; the inhaler should be stopped immediately and medical attention sought.

Why Formoterol Must Never Be Used Alone in Asthma

The SMART (Salmeterol Multicenter Asthma Research Trial) demonstrated significantly increased asthma-related mortality when long-acting beta-2 agonists were used without an inhaled corticosteroid. LABAs open the airways but do not treat the underlying eosinophilic airway inflammation that drives asthma. Without an inhaled corticosteroid, this inflammation continues unchecked beneath a veneer of symptom relief, increasing the risk of severe and fatal asthma attacks. All major asthma guidelines mandate that formoterol in asthma must always be combined with an inhaled corticosteroid.

Drug Interactions and Precautions

Key interactions are:

• Beta-blockers 

• QTc-prolonging drugs 

• Loop diuretics and corticosteroids

• Xanthines like theophylline, aminophylline)

• Pregnancy - inhaled formoterol at low doses is considered acceptable during pregnancy when benefit to the mother outweighs risk; asthma and COPD in pregnancy require active treatment to prevent hypoxia, which is more harmful to the foetus than the medication

Formoterol vs Salmeterol: Key Clinical Differences

Both formoterol and salmeterol are LABAs with a 12-hour duration of action but they differ in three clinically important ways:

• Onset of action: Formoterol acts within 1 to 3 minutes whereas salmeterol takes 10 to 20 minutes. Formoterol can be used as a reliever in the MART strategy whereas salmeterol cannot

• Receptor binding: Formoterol is a full agonist at the beta-2 receptor whereas salmeterol is a partial agonist; this makes formoterol a more potent bronchodilator per microgram

• Use in MART: Formoterol-ICS combinations are approved for MART; salmeterol-containing inhalers are not suitable for MART because of the slower onset.

FAQs

1. What is a formoterol inhaler used for?

   Formoterol inhaler is used for regular maintenance treatment of asthma and COPD. In asthma, it is always combined with an inhaled corticosteroid. In COPD, it reduces breathlessness, improves exercise tolerance and reduces exacerbations. In the MART strategy, the combination inhaler also serves as a reliever when symptoms occur.

2. Is formoterol a reliever or a preventer inhaler?

   Formoterol is a bit of both. It's a long-acting bronchodilator that opens airways quickly like a reliever but its effects last much longer so it's often used as part of regular preventer therapy rather than for occasional rescue use alone.

3. Can formoterol be used without a steroid in asthma?

   No formoterol must never be used as monotherapy in asthma. Clinical trial evidence shows significantly increased asthma-related mortality when LABAs (long acting beta-2 agonists) are used without an inhaled corticosteroid. The underlying inflammation of asthma must be treated with an ICS; formoterol treats only the airway narrowing. 

4. What is the difference between formoterol and salbutamol?

   Salbutamol is a short-acting beta-2 agonist that acts within 3 to 5 minutes and lasts 4 to 6 hours and used as a reliever for acute breathlessness. Formoterol is a long acting beta-2 agonists acts within 1 to 3 minutes and lasts 12 hours and used as a regular maintenance bronchodilator. Salbutamol is safe as monotherapy but formoterol in asthma must always be combined with an inhaled corticosteroid.

5. What is Foracort and what does it contain?

   Foracort is a combination inhaler containing formoterol (relaxes airway muscles) and budesonide (a steroid that reduces inflammation). Together they help control asthma symptoms and prevent flare-ups more effectively than either medicine would alone.

6. Can formoterol cause heart palpitations?

   Yes palpitations are recognised side effects of formoterol particularly at higher doses or in patients with pre-existing heart disease. They are caused by the residual beta-1 cardiac activity of formoterol. 

7. How quickly does formoterol work when inhaled?

   Formoterol acts fast often easing breathing difficulties within a few minutes of inhalation. Its effects then continue working steadily for up to twelve hours, making it useful for both quick relief and longer symptom control.

8. Is formoterol safe for children with asthma?

   Yes formoterol is commonly prescribed for children though the dose is carefully tailored to their age and weight. As with any asthma medication, a paediatrician should monitor the child's response and adjust treatment as needed.

9. Can formoterol be used during an acute asthma attack?

   It can help but it isn't typically the first choice for sudden, severe attacks. A fast-acting reliever inhaler is usually recommended in emergencies with formoterol continuing as part of the regular ongoing treatment plan.

10. What are the side effects of Foracort inhaler?

    Common side effects include a mild tremor, headache, throat irritation or a faster heartbeat. Most of these are temporary and manageable but persistent or severe symptoms should always be reported to a doctor promptly.

References

1. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med. 1999;160(2):594–9. https://doi.org/10.1164/ajrccm.160.2.9811100

2. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. https://doi.org/10.1056/NEJMoa1715274

3. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (MART versus best practice). Cochrane Database Syst Rev. 2013;(4):CD007313. https://doi.org/10.1002/14651858.CD007313.pub3

4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26. https://doi.org/10.1378/chest.129.1.15

5. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. GINA. 2023. https://ginasthma.org/reports